Myopia, as a result of abnormally elongating the eyeball axial length, is a common eye disorder worldwide, especially being prevalent (~85) in Asian countries. We have identified overexpressed microRNA-328 as a key factor for myopia. We designed microRNA-328 inhibitorsfiled patents for myopia treatment. By using the inhibitor via eye drop, we successfully treated myopic micerabbits. No side effecttoxicity was observed.

Our team has developed a series of “small anti-sense oligonucleotides” in eye drop form to neutralize over-expressed microRNA-328 in cellsanimal models of myopia. By utilizing our eye drops, we successfully treated myopic micerabbits. Additionally, our eye drops were shown better therapeutic effects than Atropine (the only clinically used anti-myopic eye drops). Our product by using the 

Our eye drop product is mainly used to treat schoolchildren, due to the rapid myopic development during 6-12 year olds. Because schoolchildren in developed Asian countries are requested to have periodic eyevision examinations, full records of vision tests allow children with myopia to receive treatment immediately. Our team has developed a novel anti-myopia eye drops for myopia control. The e